For the year ending 2025-12-31, TRDA made $25,421K in revenue. -$143,055K in net income. Net profit margin of -562.74%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 25,421 | 210,782 | ||
| Research and development | 142,269 | 125,306 | ||
| General and administrative | 41,050 | 38,465 | ||
| Total operating expenses | 183,319 | 163,771 | ||
| (loss) income from operations | -157,898 | 47,011 | ||
| Interest and other income | 15,072 | 19,474 | ||
| Total other income | 15,072 | 19,474 | ||
| (loss) income before provision for income taxes | -142,800 | 66,485 | ||
| Total income tax provision | 924 | 859 | ||
| Net (loss) income | -143,750 | 65,626 | ||
| Unrealized gain (loss) on marketable securities, net of tax of 0 | 695 | -238 | ||
| Total other comprehensive income (loss) | 695 | -238 | ||
| Total comprehensive (loss) income | -143,055 | 65,388 | ||
| Basic EPS | -3.47 | 1.76 | ||
| Diluted EPS | -3.47 | 1.68 | ||
| Basic Average Shares | 41,371,486 | 37,306,363 | ||
| Diluted Average Shares | 41,371,486 | 39,003,169 | ||
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)